The INITIATOR Study: Pilot Data on Real-World Clinical and Economic Outcomes in US Patients with Type 2 Diabetes Initiating Injectable Therapy
| العنوان: | The INITIATOR Study: Pilot Data on Real-World Clinical and Economic Outcomes in US Patients with Type 2 Diabetes Initiating Injectable Therapy |
|---|---|
| المؤلفون: | Ralph Quimbo, Lee Brekke, Wenli Hu, William H. Crown, Robert Cuddihy, Sarah Thayer, Michael Grabner, Swetha Raparla, Mark J. Cziraky, Wenhui Wei, Erin Buysman |
| المصدر: | Advances in Therapy |
| بيانات النشر: | Springer Healthcare, 2013. |
| سنة النشر: | 2013 |
| مصطلحات موضوعية: | Blood Glucose, Male, endocrine system diseases, Databases, Factual, Cost-Benefit Analysis, Insulin Glargine, Pilot Projects, Type 2 diabetes, Severity of Illness Index, Cohort Studies, Glucagon-Like Peptide 1, Pharmacology (medical), Disposable Equipment, Original Research, Medicine(all), General Medicine, Health Care Costs, Middle Aged, Insulin, Long-Acting, Treatment Outcome, Female, Cohort study, medicine.drug, Adult, medicine.medical_specialty, Injections, Subcutaneous, Drug Administration Schedule, Statistics, Nonparametric, Injectable treatment, Diabetes mellitus, Treatment initiation, Type 2 diabetes mellitus, medicine, Humans, Hypoglycemic Agents, Intensive care medicine, Glycemic, Aged, Retrospective Studies, Dose-Response Relationship, Drug, Insulin glargine, business.industry, Liraglutide, Syringes, Type 2 Diabetes Mellitus, nutritional and metabolic diseases, Retrospective cohort study, medicine.disease, United States, Surgery, Diabetes Mellitus, Type 2, business |
| الوصف: | Introduction Type 2 diabetes mellitus (T2DM) progression often results in treatment intensification with injectable therapy to maintain glycemic control. Using pilot data from the Initiation of New Injectable Treatment Introduced after Anti-diabetic Therapy with Oral-only Regimens study, real-world treatment patterns among T2DM patients initiating injectable therapy with insulin glargine or liraglutide were assessed. Methods This was a retrospective analysis of claims from the OptumInsight™ (OI; January 1, 2010 to July 30, 2010) and HealthCore® (HC; January 1, 2010 to June 1, 2010) health insurance databases. Baseline characteristics, health care resource utilization, and costs were compared between adults with T2DM initiating injectable therapy with insulin glargine pen versus liraglutide. Follow-up outcomes, including glycated hemoglobin A1c (A1C), hypoglycemia, health care utilization, and costs, were assessed. Results At baseline, almost one in three liraglutide patients (OI, n = 363; HC, n = 521) had A1C |
| اللغة: | English |
| تدمد: | 1865-8652 0741-238X |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::eb0afa6b3907511a60489e2eb5ba1dab http://europepmc.org/articles/PMC3898354 |
| حقوق: | OPEN |
| رقم الأكسشن: | edsair.doi.dedup.....eb0afa6b3907511a60489e2eb5ba1dab |
| قاعدة البيانات: | OpenAIRE |
Find this article in full text from Springer Verlag. | تدمد: | 18658652 0741238X |
|---|